Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics

Lack Of Clarity Over FDA Expectations And Mid-Cycle Changes Add To Challenges

16 Mar 2023

With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks to Generics Bulletin about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.

Sven Dethlefs of Teva — Teva’s Sven Dethlefs talks about the challenges of bringing complex generics to market • Source: Teva

Teva continues to see significant potential in complex generics in the US, with a number of opportunities in its pipeline and some high-value targets in its sights.

However, speaking to Generics Bulletin, Sven Dethlefs – Teva’s executive vice president for North America commercial – has outlined some...